Roberto Arrojo

Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody–Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers

Thomas M. Cardillo, Serengulam V. Govindan, Robert M. Sharkey et al. · Bioconjugate Chemistry · 2015 · 296 citations

Medicine, Oncology, Pharmacology +17

Synthetic Lethality Exploitation by an Anti–Trop-2-SN-38 Antibody–Drug Conjugate, IMMU-132, Plus PARP Inhibitors in <i>BRCA1/2</i> –wild-type Triple-Negative Breast Cancer

Thomas M. Cardillo, Robert M. Sharkey, Diane L. Rossi et al. · Clinical Cancer Research · 2017 · 127 citations

Medicine, Oncology, Pharmacology +17

Predictive biomarkers for sacituzumab govitecan efficacy in Trop-2-expressing triple-negative breast cancer

Thomas M. Cardillo, Diane L. Rossi, Maria Zalath et al. · Oncotarget · 2020 · 52 citations · Full text

Medicine, Oncology, Pharmacology +17

Targeting both IGF-1R and mTOR synergistically inhibits growth of renal cell carcinoma in vitro

Thomas M. Cardillo, Preeti Trisal, Roberto Arrojo et al. · BMC Cancer · 2013 · 33 citations · Full text

Medicine, Oncology, Pharmacology +17

Sacituzumab govitecan plus platinum-based chemotherapy mediates significant antitumor effects in triple-negative breast, urinary bladder, and small-cell lung carcinomas

Thomas M. Cardillo, Maria Zalath, Roberto Arrojo et al. · Oncotarget · 2024 · 13 citations · Full text

Medicine, Oncology, Pharmacology +9